Company Filing History:
2 out of 34 
1 out of 32 
1 out of 1 Years Active: 2014-2020
Title: The Innovator Behind Pyrimido-Pyridazinone Compounds: Karunasree Kunta
Introduction
Karunasree Kunta is a distinguished inventor based in Hyderabad, Telangana, India. With an impressive portfolio comprising four patents, she has made significant contributions to the field of medicinal chemistry. Her work primarily focuses on innovative compounds that address crucial health issues, particularly in the area of inflammation treatment.
Latest Patents
Among her most notable patents, Karunasree has developed novel pyrimido-pyridazinone compounds. The present application details methods for preparing and utilizing these compounds in therapeutic contexts. Specifically, these compounds are advantageous for treating inflammation in patients. One embodiment of her latest work includes a specific pyrimido-pyridazinone compound represented by a defined Formula (I), showcasing her innovative approach to pharmaceutical development.
Career Highlights
Throughout her career, Karunasree has made impactful strides in the pharmaceutical industry. She has worked with well-known companies such as Asana Biosciences, LLC and Endo Pharmaceuticals Inc., where she utilized her expertise to advance drug development. Her role in these organizations has significantly contributed to her recognition as a leading inventor in her field.
Collaborations
In her journey of innovation, Karunasree has collaborated with esteemed colleagues including Aranapakam Mudumbai Venkatesan and Roger Astbury Smith. These partnerships have enhanced her research capabilities and have played a crucial role in furthering her inventive processes.
Conclusion
Karunasree Kunta stands as a remarkable figure in the realm of scientific innovation, particularly with her groundbreaking work on pyrimido-pyridazinone compounds. Her dedication to addressing health challenges through her inventions cements her status as an influential inventor. With continued collaboration and innovation, her future contributions are highly anticipated in the pharmaceutical sector.